文献速递腹部介入MR

钆塞酸增强MRI特征预测早期肝细胞癌(<3 cm)经动脉化疗栓塞术后治疗结局

Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization.
PubMed 文献 · Acad Radiol · 2022-02-10

本回顾性研究纳入135例以传统TACE作为一线治疗的BCLC 0或A期(<3 cm)肝细胞癌患者,评估治疗前钆塞酸增强MRI特征与术后肿瘤反应及生存的关系。中位随访47个月,1个月随访时90例(67%)达完全缓解。多发、中央位置和边缘不规则与较差的肿瘤反应或生存显著相关。

要点

  • 肿瘤数目、中央位置与完全缓解呈负相关(OR分别为0.602和0.349)。
  • 边缘不规则与较差的无进展生存和总生存显著相关(PFS HR=3.099,OS HR=1.985)。
  • 治疗前钆塞酸增强MRI的多发、中央位置和边缘不规则提示TACE后预后较差。

核心结论

  • 钆塞酸增强MRI上的多发、中央位置和边缘不规则是早期肝细胞癌患者接受传统TACE后预后不良的显著相关因素。

研究设计与样本

  • 回顾性研究纳入135例以传统TACE作为一线治疗的BCLC 0或A期(<3 cm)肝细胞癌患者,治疗前均行钆塞酸增强MRI,评估治疗前临床特征和MRI特征,并分析治疗后肿瘤反应、无进展生存和总生存。

诊断标准与关键数值

  • 肿瘤数目与完全缓解呈负相关(OR 0.602,95%CI 0.375-0.967)。
  • 中央位置与完全缓解呈负相关(OR 0.349,95%CI 0.145-0.837)。
  • 肿瘤数目与较差PFS相关(HR=1.444,95%CI=1.124-1.854),与较差OS相关(HR=1.459,95%CI=1.018-2.090)。
  • 中央位置与较差PFS相关(HR=1.664,95%CI=1.038-2.667),与较差OS相关(HR=1.890,95%CI=1.021-3.497)。
  • 边缘不规则与较差PFS相关(HR=3.099,95%CI=1.953-4.979),与较差OS相关(HR=1.985,95%CI=1.084-3.634)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Magnetic resonance imaging (MRI) is the most useful imaging tool for small hepatocellular carcinoma (HCC) evaluation. Patients undergoing transarterial chemoembolization (TACE) might have predictive imaging prognostic factors. This study aimed to find predictive gadoxetic acid (GA)-enhanced MRI features that affect tumor response and outcomes in patients with early HCC who underwent conventional TACE.

MATERIALS AND METHODS: Among patients who underwent conventional TACE as a first-line treatment for Barcelona clinic liver cancer stage 0 or A (<3 cm), 135 patients who underwent GA-enhanced MRI before treatment were included in this retrospective study. The patients' pretreatment clinical characteristics and MRI features were evaluated. Post-treatment tumor response, progression-free survival (PFS), and overall survival (OS) were also investigated.

RESULTS: The median follow-up period was 47 (range: 7-133) months, with 90 (67%) patients showing complete remission (CR) at the 1-month follow-up after TACE. Tumor number (odds ratio [OR] 0.602, 95% confidence interval [CI]: 0.375-0.967), central location (OR: 0.349, 95% CI: 0.145-0.837) were inversely associated with CR achievement. Median PFS and OS time were 22 (range: 1-133) and 67 (range: 7-133) months, respectively. The MRI features affecting poor survival outcomes were tumor number (PFS: hazard ratio [HR]=1.444, 95% CI=1.124-1.854; OS: HR=1.459, 95% CI=1.018-2.090), central location (PFS: HR=1.664, 95% CI=1.038-2.667; OS: HR=1.890, 95% CI=1.021-3.497), and marginal irregularity (PFS: HR=3.099, 95% CI=1.953-4.979; OS: HR=1.985, 95% CI=1.084-3.634).

CONCLUSION: Multiplicity, central location, and marginal irregularity of HCC on GA-enhanced MRI were significant factors associated with poor prognosis of patients with early HCC after conventional TACE.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Lee, Jeong, Heo, et al. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization. Acad Radiol. 2022. PMID: 35151549. doi:10.1016/j.acra.2021.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。